CELZHealthcare · BiotechnologyCELZ Stock Forecast: Creative Medical Technology Holdings, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Creative Medical Technology Holdings, Inc. hold a median 12-month price target of $20 — +2957.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
CELZ stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Creative Medical Technology Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Creative Medical Technology Holdings, Inc. — and when they’d sell — is the membership.
CELZ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CELZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +2957.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Feb 2022 | Roth Capital | Initiates | Buy | $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CELZ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Creative Medical Technology Holdings, Inc. (CELZ) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 2.8×
- Price / sales
- 1435.8×
- Price / book
- 0.4×
- EV / EBITDA
- 0.6×
Cheaper than 68% of US stocks
Cheaper than 1% of US stocks
Cheaper than 86% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −198049.6%
- Net margin
- 63.4%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 97% of US stocks
- Return on equity
- −81.2%
- Return on assets
- −50.2%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CELZ vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELZ appears on the weeks it earns a place.
Frequently asked questions about CELZ stock
What is the CELZ stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Creative Medical Technology Holdings, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CELZ stock a buy right now?
Of the 1 analysts covering Creative Medical Technology Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Creative Medical Technology Holdings, Inc. 35 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CELZ?
As at 1 Aug 2026, Creative Medical Technology Holdings, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
Will CELZ stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +2957.2% from the last close, and Ticker Nerd's factor model ranks Creative Medical Technology Holdings, Inc. 35 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CELZ stock forecast for 2030?
No analyst covering Creative Medical Technology Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
How has CELZ stock performed over the past year?
Creative Medical Technology Holdings, Inc. returned -77.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Creative Medical Technology Holdings, Inc. do?
Creative Medical Technology Holdings Inc. is a clinical- and commercial-stage biotechnology company specializing in regenerative medicine and immunotherapy.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings Inc. is a clinical- and commercial-stage biotechnology company specializing in regenerative medicine and immunotherapy. The company focuses on stem cell–based therapies addressing unmet needs across orthopedics, endocrinology, immunology, urology, and gynecology. Its pipeline includes proprietary platforms such as Olastrocel, a leading allogeneic cell therapy candidate for chronic lower back pain and metabolic indications, as well as ImmCelz, a personalized immune cell technology designed to modulate immune responses. Creative Medical Technology Holdings Inc. also develops and commercializes procedures and products for sexual health and infertility, including applications for erectile dysfunction, female sexual dysfunction, and premature ovarian failure. Headquartered in Phoenix, Arizona and founded in 1998, the company operates through multiple cell-based platforms using adult and perinatal stem cell technologies, aiming to deliver clinically validated regenerative treatments to patients via physician networks and specialized clinical programs.
CEO Mr. Timothy Warbington · 4 employees · United States · https://www.creativemedicaltechnology.com